RPRX - Royalty Pharma acquires Oxlumo royalty interest from Dicerna

Royalty Pharma (RPRX) has acquired the royalty interest of Oxlumo™ (lumasiran) from Dicerna Pharmaceuticals (DRNA) for a total consideration of up to $240M.As part of the agreement, Dicerna is entitled to receive $180M as an upfront cash payment in addition to contingent sales-based milestone payments worth up to $60M.The transaction has extended Dicerna’s projected cash runway sufficiently enough to fund its clinical and operational targets into 2024, the company said.Following a 2020 cross-license agreement between Dicerna and Alnylam Pharmaceuticals (ALNY) related to the companies’ primary hyperoxaluria (“PH”) programs, Dicerna was entitled to royalties on global net product sales of Oxlumo.It is authorized by the FDA and European Medicines Agency (“EMA”) for the treatment of PH Type 1.

For further details see:

Royalty Pharma acquires Oxlumo royalty interest from Dicerna